|
TNFSF13B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To characterize baseline gene expression and pharmacodynamically induced changes in whole blood gene expression in 1,760 systemic lupus erythematosus (SLE) patients from 2 phase III, 52-week, randomized, placebo-controlled, double-blind studies in which patients were treated with the BAFF-blocking IgG4 monoclonal antibody tabalumab.
|
27723281 |
2017 |
|
TNFSF13B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dysregulation of BAFF is relatively common in Chinese patients with SLE.
|
17506477 |
2007 |
|
TNFSF13B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study was conducted to screen for polymorphisms of human BLYS, and to examine whether they are involved in the genetic susceptibility to human SLE and RA.
|
12424625 |
2002 |
|
TNFSF13B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Areas covered: In addition to belimumab, three other BAFF antagonists (atacicept, blisibimod, tabalumab) that biologically differ from belimumab are being or have been evaluated in SLE late-stage clinical trials.
|
28164726 |
2017 |
|
TNFSF13B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
B cell alterations during BAFF inhibition with belimumab in SLE.
|
30593436 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the expression of the cytokines BAFF and APRIL and their association with the receptors BAFF-R and TACI on CD3+ T cells and to evaluate Th1/Th2/Th17 cytokine profile in patients with SLE.
|
30467093 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-BAFF SLE group displayed increased rates of both plaque formation and arterial wall thickening (defined as IMT>0.90 mm) compared to patients with low BAFF levels (58.1% vs 43.6%, p:0.048 and 38.6% vs 23.2%, p-value: 0.024, respectively).
|
29859654 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 2011, the anti-BAFF monoclonal antibody, belimumab, became the first FDA-approved drug for SLE in 50+ years.
|
31657965 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, surprisingly, T-cell-deficient BAFF transgenic (Tg) mice develop SLE similar to T-cell-sufficient BAFF Tg mice, and the disease was linked to innate activation of B cells and production of proinflammatory autoantibody isotypes.
|
18172443 |
2008 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the trial, we also examined whether overexpression of an IFNalpha/beta-inducible gene signature in whole blood could serve as a pharmacodynamic biomarker to evaluate IFNalpha neutralization and investigated downstream effects of neutralizing IFNalpha on BAFF and other key signaling pathways, i.e., granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-10 (IL-10), tumor necrosis factor alpha (TNFalpha), and IL-1beta, in SLE.
|
19479852 |
2009 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
One possible mechanism of increasing BAFF production in SLE is proposed in this study whereby B cell activation, antibody production and ICs stimulated monocytes may create a vicious cycle that leads to B cell hyperactivity, which can be of importance for SLE etiopathogenesis.
|
28485798 |
2017 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these findings highlight how multiple signaling pathways integrate to promote class-switched autoAb production by transitional B cells, events that likely impact the pathogenesis of SLE and other BAFF-dependent autoimmune diseases.
|
30373855 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The B cell survival factor (TNFSF13B/BAFF) is often elevated in autoimmune diseases and is targeted in the clinic for the treatment of systemic lupus erythematosus.
|
29572442 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice transgenic (Tg) for BAFF develop an autoimmune condition similar to systemic lupus erythematosus.
|
11781351 |
2002 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with murine ICOSL/BAFF bispecific or combination therapy was more efficacious than single ICOSL or BAFF inhibitor in mouse NZB/NZW lupus model.
|
30789152 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since lupus nephritis is the main cause of morbidity and mortality for SLE patients, the aim of this study was to investigate whether renal tubular epithelial cells (TEC) are an important source of BAFF and thus may contribute to the pathogenesis and progression of SLE.
|
28659046 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of murine systemic lupus erythematosus in the absence of BAFF.
|
31493335 |
2020 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
High BAFF expression is related to active disease, renal and hematological involvement; therefore, it could be considered as follow-up biomarker in SLE patients.
|
30747361 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, TNFSF13B BAFF-var was significantly associated with SLE in the Spanish (p = 0.001, OR = 1.41, 95% CI = 1.14-1.74) and the German cohorts (p = 0.030, OR = 1.86, 95% CI = 1.05-3.28), with a statistically significant p-value obtained in the meta-analysis (p = 0.0002, OR = 1.46, 95% CI = 1.09-2.32).
|
29844438 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The identification and characterization of the receptor for TALL-1 provides useful information for the development of a treatment for B cell-mediated autoimmune diseases such as systemic lupus erythematosus.
|
10880535 |
2000 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAFF antagonists have been effective in the prevention and treatment of SLE in several different murine models.
|
18613835 |
2008 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeted inhibitors of B-cell activating factor (BAFF) have been evaluated in phase III trials in over 4000 patients with systemic lupus erythematosus (SLE).
|
29563108 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAFF protein also correlated with anti-nuclear antibodies, and autoantibodies against double-stranded DNA, single-stranded DNA, and ribonucleoprotein, and Systemic Lupus Erythematosus Disease Activity Index scores in DLE patients.
|
24315762 |
2014 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the efficacy and safety of tabalumab, an anti-B cell activating factor (BAFF) antibody, in combination with standard of care (SoC) therapy in Japanese patients with active systemic lupus erythematosus (SLE).
|
27471815 |
2017 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus.
|
26339644 |
2015 |